Leading the Way in Life Science Technologies

GEN Exclusives

More »

Nov. 15, Vol. 31, No. 20

    • Feature Articles

      • Flow Cytometry Shifting Gears
      • Kathy Liszewski
      • Although established more than 30 years ago, the field of flow cytometry continues to grow and advance. It remains an indispensable tool for clinicians and researchers. The “Northwest Regional Cytometry” meeting held earlier this year focused on cyt ... more »
      • GEN's 30th Anniversary: Molecular Diagnostics
      • In this issue’s “Biomarket Trends” column, Frost & Sullivan analyst Jonathan Witonsky notes that revenues from worldwide sales of molecular diagnostics were estimated to reach $4 billion last year and to rise to $6 billion by 2014 based on a com ... more »
      • Gene-Expression Profiling Finds Niche
      • Diana Gitig, Ph.D.
      • How can one take the measure of a cell? What most characterizes it? In this genomic age, one possible answer is that a cell can be defined by a profile of all of the genes it is expressing. Microarray technology and next-generation sequencing method ... more »
      • Microfluidics Making Bigger Impression
      • Vicki Glaser
      • Microfluidics technology development is entering a new phase, according to Andreas Manz, Ph.D., head of research at the Korea Institute of Science and Technology, Saarbrücken, Germany. Now that the initial patents covering the fundamental techn ... more »
    • Tutorials

      • Advances in Sophisticated Genome Editing
      • Keith Hansen
      • CompoZr® zinc finger nucleases (ZFNs) from Sigma® Life Science enable efficient and affordable gene editing across many species and cell types, including humans, rats, mice, frogs, rabbits, pigs, cattle, C. elegans , and Drosophila . Rec ... more »
      • Enhanced Albumin Fusion Technology
      • Jason Cameron
      • The development of efficacious protein-based therapeutics is often hindered because many exhibit a short plasma half-life. As a result, technologies addressing the extension of protein half-life are attracting considerable attention within the pharm ... more »
    • Corporate Profile

      • Samsung Stakes Out Biopharma Position
      • Carol Potera
      • Samsung, the South Korean company best known to Americans for televisions and other electronic equipment, is branching out to make biopharmaceuticals. In May, ground was broken for Samsung Biologics located in Incheon, South Korea; full-scale operat ... more »
    • BioMarket Trends

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »